The goal of Core C (Biostatistics &Data Management) is to provide expert guidance and consultation in the biostatistical and data management aspects of the design, conduct, and analysis of research projects generated by the P01. Core C will provide statistical collaboration and also support the P01 's clinical research activities by designing, implementing and operating a data management system for the projects' gene therapy clinical trials. Core C will provide its services to P01 projects at every stage of the research: Prior to the initiation of studies, Core staff will consult with P01 investigators to help them select efficient designs and sample sizes that will give adequate power to address study objectives. For gene therapy clinical trials, they will establish data management systems and design case report forms that collect all required information in an unambiguous way. As studies proceed, Core staff will enter data, manage and monitor clinical trial databases, implement and execute data quality control activities, and prepare data reports. When studies are finished, the Core will conduct correct and efficient data analyses, prepare any necessary graphs and tables, assist investigators with the preparation of presentations and manuscripts, and consult on the design of subsequent research. The work of Core C will involve close integration with the efforts of all the research projects. Core C staff members have extensive experience supporting cancer research, with strong backgrounds in basic science, translational research, clinical trials, research computing, and data management. With their many years of experience in applied and methodologic statistical research, they stand ready to choose the best approaches from the pool of existing methods and to adapt or develop new methods as needed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066726-13
Application #
7900460
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
13
Fiscal Year
2009
Total Cost
$133,903
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moon, Edmund K; Wang, Liang-Chuan S; Bekdache, Kheng et al. (2018) Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology 7:e1395997
Aggarwal, Charu; Haas, Andrew R; Metzger, Susan et al. (2018) Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. Mol Ther 26:1198-1205
Klampatsa, Astero; Haas, Andrew R; Moon, Edmund K et al. (2017) Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers (Basel) 9:
Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47
Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90
O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60
Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN? Combined with Chemotherapy. Clin Cancer Res 22:3791-800
Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51
Andy, Uduak U; Harvie, Heidi S; Smith, Ariana L et al. (2015) Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn 34:424-8

Showing the most recent 10 out of 85 publications